These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15752926)

  • 21. [Beta cells in Type II diabetes: culprit or victim?].
    Scheen AJ; Paquot N; Lefebvre PJ
    Journ Annu Diabetol Hotel Dieu; 1991; ():153-69. PubMed ID: 1886327
    [No Abstract]   [Full Text] [Related]  

  • 22. Early detection and integrated management of dysglycemia in cardiovascular disease: a key factor for decreasing the likelihood of future events.
    Anselmino M; Mellbin L; Wallander M; Rydén L
    Rev Cardiovasc Med; 2008; 9(1):29-38. PubMed ID: 18418307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restoring a functional beta-cell mass in diabetes.
    Pipeleers D; Chintinne M; Denys B; Martens G; Keymeulen B; Gorus F
    Diabetes Obes Metab; 2008 Nov; 10 Suppl 4():54-62. PubMed ID: 18834433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes.
    Leiter LA
    Diabet Med; 2005 Aug; 22(8):963-72. PubMed ID: 16026359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of diabetes in cardiovascular patients: diabetic heart disease.
    Peter R; Cox A; Evans M
    Heart; 2008 Mar; 94(3):369-75. PubMed ID: 18276822
    [No Abstract]   [Full Text] [Related]  

  • 26. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
    Mu J; Woods J; Zhou YP; Roy RS; Li Z; Zycband E; Feng Y; Zhu L; Li C; Howard AD; Moller DE; Thornberry NA; Zhang BB
    Diabetes; 2006 Jun; 55(6):1695-704. PubMed ID: 16731832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
    Malesker MA
    Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The accelerator hypothesis and increasing incidence of type 1 diabetes.
    Fourlanos S; Harrison LC; Colman PG
    Curr Opin Endocrinol Diabetes Obes; 2008 Aug; 15(4):321-5. PubMed ID: 18594271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SUIT, secretory units of islets in transplantation: An index for therapeutic management of islet transplanted patients and its application to type 2 diabetes.
    Yamada Y; Fukuda K; Fujimoto S; Hosokawa M; Tsukiyama K; Nagashima K; Fukushima M; Suzuki H; Toyoda K; Sassa M; Funakoshi S; Inagaki N; Taniguchi A; Sato TS; Matsumoto S; Tanaka K; Seino Y
    Diabetes Res Clin Pract; 2006 Dec; 74(3):222-6. PubMed ID: 16707190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of postprandial hyperglycemia in cardiovascular disease.
    Fava S
    Expert Rev Cardiovasc Ther; 2008 Jul; 6(6):859-72. PubMed ID: 18570623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of beta-cell management in type 2 diabetes.
    Standl E
    Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid management with statins in type 2 diabetes mellitus.
    Irons BK; Kroon LA
    Ann Pharmacother; 2005 Oct; 39(10):1714-9. PubMed ID: 16118264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal diabetes management during medical weight loss for cardiovascular risk reduction.
    Nori Janosz KE; Miller WM; Odom J; Lillystone M; McCullough PA
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):761-75. PubMed ID: 16076284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperglycaemia and cardiovascular disease.
    Bartnik M; Norhammar A; Rydén L
    J Intern Med; 2007 Aug; 262(2):145-56. PubMed ID: 17645583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic strategies for improved outcomes for the hyperglycemic hospitalized patient with diabetes mellitus.
    Vasa F
    Am J Cardiol; 2005 Aug; 96(4A):41E-46E. PubMed ID: 16098843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update.
    Ceriello A; Davidson J; Hanefeld M; Leiter L; Monnier L; Owens D; Tajima N; Tuomilehto J;
    Nutr Metab Cardiovasc Dis; 2006 Oct; 16(7):453-6. PubMed ID: 16934443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin therapy in type 2 diabetes.
    Wyne KL; Mora PF
    Endocr Res; 2007; 32(3):71-107. PubMed ID: 18092196
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes.
    Caballero AE
    J Diabetes Complications; 2009; 23(2):143-52. PubMed ID: 18413192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperglycemia alters the beta-cell sensitivity to beta-endorphin in noninsulin-dependent diabetic subjects.
    Giugliano D; Cozzolino D; Giunta R; Coppola L; Saccomanno F; Torella R
    Horm Metab Res; 1988 May; 20(5):306-7. PubMed ID: 2969855
    [No Abstract]   [Full Text] [Related]  

  • 40. Lifestyle modification and endothelial function in obese subjects.
    Hamdy O
    Expert Rev Cardiovasc Ther; 2005 Mar; 3(2):231-41. PubMed ID: 15853597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.